Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI

被引:4
|
作者
Woo, Sungmin [1 ,2 ]
Becker, Anton S. [1 ,2 ]
Das, Jeeban P. [1 ]
Ghafoor, Soleen [3 ]
Arita, Yuki [1 ]
Benfante, Nicole [4 ]
Gangai, Natalie [1 ]
Teo, Min Yuen [5 ]
Goh, Alvin C. [4 ]
Vargas, Hebert A. [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10065 USA
[2] NYU Langone Hlth, Dept Radiol, 660 1st Ave, New York, NY 10016 USA
[3] Univ Hosp Zurich, Inst Diagnost & Intervent Radiol, Ramistr 100, CH-8091 Zurich, Switzerland
[4] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, 1275 York Ave, New York, NY 10065 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Med, Genitourinary Oncol Serv, New York, NY 10065 USA
关键词
Biparametric; Cystectomy; Magnetic resonance imaging; Muscle-invasive bladder cancer; Multiparametric; Neoadjuvant chemotherapy; Prognosis; Survival; Urothelial; Response assessment; CONTRAST-ENHANCED MRI; THERAPEUTIC RESPONSE; CELL CARCINOMA; DATA SYSTEM; CYSTECTOMY; CHEMORADIOTHERAPY; METHOTREXATE; VINBLASTINE; CISPLATIN; SURVIVAL;
D O I
10.1186/s40644-023-00632-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundNeoadjuvant chemotherapy (NAC) before radical cystectomy is standard of care in patients with muscle-invasive bladder cancer (MIBC). Response assessment after NAC is important but suboptimal using CT. We assessed MRI without vs. with intravenous contrast (biparametric [BP] vs. multiparametric [MP]) for identifying residual disease on cystectomy and explored its prognostic role.MethodsConsecutive MIBC patients that underwent NAC, MRI, and cystectomy between January 2000-November 2022 were identified. Two radiologists reviewed BP-MRI (T2 + DWI) and MP-MRI (T2 + DWI + DCE) for residual tumor. Diagnostic performances were compared using receiver operating characteristic curve analysis. Kaplan-Meier curves and Cox proportional-hazards models were used to evaluate association with disease-free survival (DFS).Results61 patients (36 men and 25 women; median age 65 years, interquartile range 59-72) were included. After NAC, no residual disease was detected on pathology in 19 (31.1%) patients. BP-MRI was more accurate than MP-MRI for detecting residual disease after NAC: area under the curve = 0.75 (95% confidence interval (CI), 0.62-0.85) vs. 0.58 (95% CI, 0.45-0.70; p = 0.043). Sensitivity were identical (65.1%; 95% CI, 49.1-79.0) but specificity was higher in BP-MRI compared with MP-MRI for determining residual disease: 77.8% (95% CI, 52.4-93.6) vs. 38.9% (95% CI, 17.3-64.3), respectively. Positive BP-MRI and residual disease on pathology were both associated with worse DFS: hazard ratio (HR) = 4.01 (95% CI, 1.70-9.46; p = 0.002) and HR = 5.13 (95% CI, 2.66-17.13; p = 0.008), respectively. Concordance between MRI and pathology results was significantly associated with DFS. Concordant positive (MRI+/pathology+) patients showed worse DFS than concordant negative (MRI-/pathology-) patients (HR = 8.75, 95% CI, 2.02-37.82; p = 0.004) and compared to the discordant group (MRI+/pathology- or MRI-/pathology+) with HR = 3.48 (95% CI, 1.39-8.71; p = 0.014).ConclusionBP-MRI was more accurate than MP-MRI for identifying residual disease after NAC. A negative BP-MRI was associated with better outcomes, providing complementary information to pathological assessment of cystectomy specimens.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI
    Sungmin Woo
    Anton S. Becker
    Jeeban P. Das
    Soleen Ghafoor
    Yuki Arita
    Nicole Benfante
    Natalie Gangai
    Min Yuen Teo
    Alvin C. Goh
    Hebert A. Vargas
    Cancer Imaging, 23
  • [2] Referral for "Neoadjuvant Chemotherapy" for Muscle-Invasive Bladder Cancer to a Multidisciplinary Board: Patterns, Management and Outcomes
    Dellis, Athanasios
    Zakopoulou, Roubini
    Kougioumtzopoulou, Andromahi
    Tzannis, Kimon
    Koutsoukos, Konstantinos
    Fragkoulis, Charalampos
    Kostouros, Efthymios
    Papatsoris, Athanasios
    Varkarakis, Ioannis
    Stravodimos, Konstantinos
    Boutati, Eleni
    Pagoni, Stamata
    Seferlis, Miltiadis
    Chrisofos, Michael
    Kouloulias, Vasilios
    Ntoumas, Konstantinos
    Deliveliotis, Charalambos
    Constantinides, Constantine
    Dimopoulos, Meletios A.
    Bamias, Aristotelis
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 5941 - 5955
  • [3] Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial
    Hussain, Syed A.
    Porta, Nuria
    Hall, Emma
    Salawu, Abdulazeez
    Lewis, Rebecca
    Sreenivasan, Thiagarajan
    Wallace, Jan
    Crundwell, Malcolm
    Jenkins, Peter
    Tremlett, Jean
    Huddart, Robert
    James, Nicholas D.
    EUROPEAN UROLOGY, 2021, 79 (02) : 307 - 315
  • [4] Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer
    Reignier, Pierre-Louis
    Gauthier, Helene
    Hennequin, Christophe
    Aussedat, Quiterie
    Xylinas, Evanguelos
    Desgrandchamps, Francois
    Culine, Stephane
    Masson-Lecomte, Alexandra
    Dumont, Clement
    WORLD JOURNAL OF UROLOGY, 2023, 41 (11) : 3249 - 3255
  • [5] Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Nationwide Analysis of Eligibility, Utilization, and Outcomes
    Nikulainen, Ilkka
    Salminen, Antti P.
    Hogerman, Mikael
    Seikkula, Heikki
    Bostrom, Peter J.
    Finnish National Cystectomy Database Res Grp
    CANCERS, 2025, 17 (03)
  • [6] Diagnostic accuracy and discriminative power of biparametric versus multiparametric MRI in predicting muscle-invasive bladder cancer
    Elshetry, Al Shaimaa Fathi
    El-fawakry, Rabab Mahmoud
    Hamed, Enas Mahmoud
    Metwally, Maha Ibrahim
    Zaid, Nesma Adel
    EUROPEAN JOURNAL OF RADIOLOGY, 2022, 151
  • [7] Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California
    Fairey, Adrian S.
    Daneshmand, Siamak
    Quinn, David
    Dorff, Tanya
    Dorin, Ryan
    Lieskovsky, Gary
    Schuckman, Anne
    Cai, Jie
    Miranda, Gus
    Skinner, Eila C.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (08) : 1737 - 1743
  • [8] Evaluating biparametric MRI for diagnosing muscle-invasive bladder cancer with variant urothelial histology: a multicenter study
    Liu, Peikun
    Cai, Lingkai
    Que, Hongliang
    Jiang, Meihua
    Jiang, Xuping
    Liang, Bo
    Wang, Gongcheng
    Jiang, Linjing
    Yang, Xiao
    Lu, Qiang
    CANCER IMAGING, 2025, 25 (01)
  • [9] Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
    Becker, Russell E. N.
    Meyer, Alexa R.
    Brant, Aaron
    Reese, Adam C.
    Biles, Michael J.
    Harris, Kelly T.
    Netto, George
    Matoso, Andres
    Hoffman-Censits, Jean
    Hahn, Noah M.
    Choi, Woonyoung
    McConkey, David
    Pierorazio, Phillip M.
    Johnson, Michael H.
    Schoenberg, Mark P.
    Kates, Max R.
    Baras, Alex
    Bivalacqua, Trinity J.
    EUROPEAN UROLOGY, 2021, 79 (03) : 364 - 371
  • [10] DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer
    Korner, Stefanie Korsgaard
    Dreyer, Thomas
    Carus, Andreas
    Dohn, Line Hammer
    Joensen, Ulla Nordstrom
    Lam, Gitte Wrist
    Jensen, Niels Viggo
    Fabrin, Knud
    Jensen, Thor Knak
    Pappot, Helle
    Agerbaek, Mads
    Jensen, Jorgen Bjerggaard
    SCANDINAVIAN JOURNAL OF UROLOGY, 2024, 59 : 39 - 46